{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:28:50Z","timestamp":1784132930266,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.semarthrit.2024.152385","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:32:14Z","timestamp":1706589134000},"page":"152385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Identification of outcome domains in primary Sj\u00f6gren's disease: A scoping review by the OMERACT Sj\u00f6gren disease working group"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-3824","authenticated-orcid":false,"given":"Yann","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Beydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Foulquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Bouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M","family":"Hammitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara S","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152385_bib0001","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0002","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0003","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/acr.21887","article-title":"Risk of non-Hodgkin's lymphoma in primary Sj\u00f6gren's syndrome: a population-based study","volume":"65","author":"Johnsen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/djj004","article-title":"Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype","volume":"98","author":"Smedby","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0005","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/annrheumdis-2011-200402","article-title":"Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan","volume":"71","author":"Weng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0006","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0007","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0008","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0009","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0010","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0011","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0016","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European league against rheumatism Sj\u00f6gren's syndrome disease activity index and European league against rheumatism Sj\u00f6gren's syndrome patient-reported index: a complete picture of primary sj\u00f6gren's syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/rheumatology\/40.10.1085","article-title":"Outcome measures in Sj\u00f6gren's syndrome","volume":"40","author":"Asmussen","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0019","unstructured":"Handbook O. Handbook. OMERACT Handbook n.d. https:\/\/omeracthandbook.org\/handbook (accessed March 9, 2022)."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.55.2.116","article-title":"Assessment of the European classification criteria for Sj\u00f6gren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European study group on diagnostic criteria for Sj\u00f6gren's syndrome","volume":"55","author":"Vitali","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0022","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0023","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"American college of rheumatology classification criteria for Sj\u00f6gren's syndrome: a data-driven, expert consensus approach in the SICCA cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 ACR-EULAR classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0025","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/art.41676","article-title":"Sj\u00f6gren's disease, not syndrome","volume":"73","author":"Baer","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0026","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/rheumatology\/kez370","article-title":"Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sj\u00f6gren's syndrome","volume":"59","author":"Orgeolet","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0027","first-page":"2553","article-title":"Pathogenesis-based treatments in primary Sjogren's syndrome using artificial intelligence and advanced machine learning techniques: a systematic literature review","volume":"14","author":"Foulquier","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.105109","article-title":"Can we use artificial intelligence for systematic literature review in rheumatology?","volume":"88","author":"Foulquier","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jclinepi.2021.12.005","article-title":"Tools to support the automation of systematic reviews: a scoping review","volume":"144","author":"Khalil","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0030","first-page":"1009","article-title":"Towards a universal definition of disease activity score thresholds: the AS135 score","volume":"41","author":"Foulquier","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0031","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0032","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren's syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0033","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.181096","article-title":"OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies","volume":"46","author":"Boers","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0034","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3899\/jrheum.181097","article-title":"Core domain set selection according to OMERACT filter 2.1: the OMERACT methodology","volume":"46","author":"Maxwell","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0035","unstructured":"OMERACT working group: Sj\u00f6gren's Disease n.d. https:\/\/omeract.org\/working-groups\/sjogrens\/(accessed December 24, 2023)."},{"key":"10.1016\/j.semarthrit.2024.152385_bib0013","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide-hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"Van-der-Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren's syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0037","article-title":"Efficacy and safety of acupuncture on symptomatic improvement in primary Sj\u00f6gren's syndrome: a randomized controlled trial","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0038","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/ard.2004.031393","article-title":"Lamivudine is not effective in primary Sj\u00f6gren's syndrome","volume":"64","author":"Gescuk","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0039","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren's syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0040","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.57.1.20","article-title":"Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study","volume":"57","author":"Hay","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0042","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren's Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0043","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren's syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0044","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren's syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","article-title":"Treatment of primary Sj\u00f6gren's syndrome with low-dose human interferon Alfa administered by the oromucosal route: combined phase III results","volume":"49","author":"Cummins","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0046","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0047","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-5751-6-11","article-title":"Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sj\u00f6gren's syndrome: a randomized, double-blind, placebo controlled cross-over study","volume":"6","author":"Seitsalo","year":"2007","journal-title":"J Negat Results Biomed"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0048","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0049","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0050","first-page":"2721","article-title":"Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"127","author":"Hu","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0051","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren's syndrome: a double-blind randomized control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0052","first-page":"2017","article-title":"Effectiveness of traditional Chinese medicine compound jiedutongluoshengjin granules treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled clinical trial","author":"Li","year":"2017","journal-title":"Evid-Based Complement Altern Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0053","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.16442","article-title":"Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sj\u00f6gren syndrome: a double-blind randomized controlled trial","volume":"179","author":"Cifuentes","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0054","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary sj\u00f6gren's syndrome: results from a phase ii randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0055","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0140-6736(22)01538-0","article-title":"Ianalumab in Sj\u00f6gren's syndrome: what can we learn from lupus trials? - Authors\u2019 reply","volume":"400","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0056","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10067-018-4315-8","article-title":"The efficacy and safety of total glucosides of peony in the treatment of primary Sj\u00f6gren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial","volume":"38","author":"Liu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0014","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0057","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren's syndrome patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0058","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumat"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0059","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0060","article-title":"Traditional Chinese medicine in patients with primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0061","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","author":"Felten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0062","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren's syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0063","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0064","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.explore.2021.08.002","article-title":"Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sj\u00f6gren's syndrome: A randomized controlled trial","volume":"18","author":"Shao","year":"2022","journal-title":"Explore (NY)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0065","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0066","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj\u00f6gren's syndrome patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0067","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5301\/ejo.5000229","article-title":"Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sj\u00f6gren syndrome","volume":"23","author":"Aragona","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0068","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","article-title":"Treatment of Sj\u00f6gren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study","volume":"38","author":"Moscovici","year":"2015","journal-title":"Cont Lens Anterior Eye"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0069","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/jop.2016.0149","article-title":"Tear film stability in sj\u00f6gren syndrome patients treated with hyaluronic acid versus crosslinked hyaluronic acid-based eye drops","volume":"33","author":"Cagini","year":"2017","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0070","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/09273948.2019.1587470","article-title":"Evaluation of the efficacy and safety of a novel 0.05% cyclosporin a topical nanoemulsion in primary Sj\u00f6gren's syndrome dry eye","volume":"28","author":"Kang","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0071","first-page":"269","article-title":"Oral pilocarpine for the treatment of dry eye in patients with Sj\u00f6gren's syndrome","volume":"85","author":"Felberg","year":"2021","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0072","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1120672121992680","article-title":"Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome","volume":"32","author":"Moawad","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0073","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","article-title":"Punctal plugs versus artificial tears for treating primary Sj\u00f6gren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function","volume":"33","author":"Qiu","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0074","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1097\/OPX.0000000000000668","article-title":"Effect of lid debridement-scaling in Sj\u00f6gren syndrome dry eye","volume":"92","author":"Ngo","year":"2015","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0075","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00784-007-0159-3","article-title":"The efficacy of Xialine in patients with Sj\u00f6gren's syndrome: a single-blind, cross-over study","volume":"12","author":"Alp\u00f6z","year":"2008","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0076","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1754-4505.2010.00158.x","article-title":"Effect of omega-3 and vitamin E supplementation on dry mouth in patients with Sj\u00f6gren's syndrome","volume":"30","author":"Singh","year":"2010","journal-title":"Special Care in Dentistry"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0077","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0714.2011.01038.x","article-title":"Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sj\u00f6gren's syndrome: a randomized controlled trial","volume":"40","author":"da Silva Marques","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0078","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00784-015-1444-1","article-title":"Efficacy of pastes containing CPP-ACP and CPP-ACFP in patients with Sj\u00f6gren's syndrome","volume":"19","author":"Peric","year":"2015","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0079","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/odi.13251","article-title":"Patient-related outcomes in Sj\u00f6gren syndrome treated with stimulants of salivary secretion: randomized clinical trial","volume":"26","author":"da","year":"2020","journal-title":"Oral Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0080","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10067-017-3898-9","article-title":"Low-Level laser therapy for xerostomia in primary Sj\u00f6gren's syndrome: a randomized trial","volume":"37","author":"Fidelix","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0081","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/annrheumdis-2017-212672","article-title":"Sialendoscopy enhances salivary gland function in Sj\u00f6gren's syndrome: a 6-month follow-up, randomised and controlled, single blind study","volume":"77","author":"Karagozoglu","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0082","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/odi.13019","article-title":"Effects of Xerostom(\u00ae) products on xerostomia in primary Sj\u00f6gren's syndrome: A randomized clinical trial","volume":"25","author":"L\u00f3pez-Pintor","year":"2019","journal-title":"Oral Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0083","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039599","article-title":"A randomized controlled trial to verify the irrigation of salivary glands in relieving xerostomia in patients with Sj\u00f6gren's syndrome","volume":"13","author":"Du","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0084","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ard.2007.071563","article-title":"Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sj\u00f6gren syndrome: a randomised controlled trial","volume":"67","author":"Hartkamp","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0086","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/acr.20022","article-title":"Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sj\u00f6gren's syndrome","volume":"62","author":"Virkki","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0087","doi-asserted-by":"crossref","first-page":"e30123","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren's syndrome\u2013a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0088","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00296-018-4213-z","article-title":"Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sj\u00f6gren's syndrome: a randomized-controlled trial","volume":"39","author":"Miyamoto","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0089","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren's syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brs.2020.12.004","article-title":"Transcranial direct current stimulation for fatigue in patients with Sjogren's syndrome: A randomized, double-blind pilot study","volume":"14","author":"Pinto","year":"2021","journal-title":"Brain Stimul"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0091","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/03009742.2019.1602880","article-title":"Effectiveness of resistance exercise in functional fitness in women with primary Sj\u00f6gren's syndrome: randomized clinical trial","volume":"49","author":"Minali","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152385_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.719592","article-title":"Cardiovascular effect of physical exercise on Primary Sjogren's Syndrome (pSS): randomized trial","volume":"8","author":"Garcia","year":"2021","journal-title":"Front Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722400026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:15:08Z","timestamp":1758734108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722400026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":92,"alternative-id":["S004901722400026X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152385","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of outcome domains in primary Sj\u00f6gren's disease: A scoping review by the OMERACT Sj\u00f6gren disease working group","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152385"}}